CVRx Q2 2024 revenue up 24% to $11.8M; net loss widens to $14.0M; updates FY guidance

CVRx, Inc.

2025-Q2 EPS reported -$1.69 vs consensus -$0.53 ▼ miss (-218.6%)

Q2 2024 revenue $11.8M (+24% YoY); U.S. HF revenue $10.5M (+27% YoY); net loss $14.0M ($0.65/share) vs $11.6M ($0.56) in Q2 2023.
Active implanting centers in U.S. reach 189, up 35% YoY; sales territories expanded to 42 from 39 in Q1.
Cash and equivalents $70.4M; net cash used in operating/investing $10.2M in Q2, down from $11.8M in Q1.
Hired Robert John as CRO, Dr. Philip Adamson as CMO, and other execs to strengthen commercial efforts.
FY 2024 guidance: revenue $50-53M; gross margin 83-85%; operating expenses $95-98M (narrowed from $92-98M); Q3 revenue $12.7-13.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.